Organization & Developments: Prime Medicine

Parents

Prime Medicine, Inc. (NASDAQ:PRME)*

Children

*Prime Editing is a technology that acts like a DNA word processor to “search and replace” disease-causing genetic sequences at their precise location in the genome, without causing double-strand DNA breakage.
*The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases
2019: Beam Therapeutics Announces Collaboration and Exclusive License Agreement with Prime Medicine for Prime Editing Technology
2019: Under the agreement, Beam has the exclusive right to develop prime editing technology for the creation or correction of any single-base transition mutations, as well as for the treatment of sickle cell disease, both of which Beam is already pursuing with its base editing technology.
2022: IPO Update: Prime Therapeutics Readies $151 Million U.S. IPO_ seekingalpha.com
2022: Prime Medicine: CRISPR 3.0 Compan_seekingalpha.com
2022: The firm's lead program, which is still in discovery phase, is seeking to treat Sickle Cell Disease.
2023: Prime Medicine: Gene Editing Tech With Unique Approach_seekingalpha.com
2024: Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
2024: Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
2024: Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
2025: Liu’s lab has developed two such ways to tackle rare diseases, base editing and prime editing
2025: Prime Medicine, once-buzzy biotech, announces layoffs, new CEO
2025: Prime Medicine: Gene Editing Company, Risky Investment
2025: Prime Medicine: Pressing Forward With Lead Liver Targeting Indications
2025: The Next Era of Gene Editing Will Be Disease Agnostic

Jumps

Finance & Acquisitions: Prime Medicine
Key People: Prime

Made with TheBrain